PDF(Pubmed)
Abstract：
One of the most cutting-edge, effective, and least invasive pharmaceutical innovations is the utilization of microneedles (MNs) for drug delivery, patient monitoring, diagnostics, medicine or vaccine delivery, and other medical procedures (e.g., intradermal vaccination, allergy testing, dermatology, and blood sampling). The MN-based system offers many advantages, such as minimal cost, high medical effectiveness, comparatively good safety, and painless drug application. Drug delivery through MNs can possibly be viewed as a viable instrument for various macromolecules (e.g., proteins, peptides, and nucleic acids) that are not efficiently administered through traditional approaches. This review article provides an overview of MN-based research in the transdermal delivery of hypertensive drugs. The critical attributes of microneedles are discussed, including the mechanism of drug release, pharmacokinetics, fabrication techniques, therapeutic applications, and upcoming challenges. Furthermore, the therapeutic perspective and improved bioavailability of hypertensive drugs that are poorly aqueous-soluble are also discussed. This focused review provides an overview of reported studies and the recent progress of MN-based delivery of hypertensive drugs, paving the way for future pharmaceutical uses. As MN-based drug administration bypasses first-pass metabolism and the high variability in drug plasma levels, it has grown significantly more important for systemic therapy. In conclusion, MN-based drug delivery of hypertensive drugs for increasing bioavailability and patient compliance could support a new trend of hypertensive drug delivery and provide an alternative option, overcoming the restrictions of the current dosage forms.
摘要：
最尖端的,有效,侵入性最小的药物创新是利用微针(MNs)进行药物输送，病人监护,诊断,药物或疫苗交付，和其他医疗程序(例如，皮内疫苗接种，过敏测试,皮肤病学,和血液采样）。基于MN的系统提供了许多优点，例如最小的成本，医疗效果高,相对较好的安全性，和无痛药物应用。通过MN的药物递送可能被视为各种大分子的可行工具(例如，蛋白质，肽，和核酸）不能通过传统方法有效施用。本文综述了基于MN的高血压药物经皮给药研究。讨论了微针的关键属性，包括药物释放机制，药代动力学，制造技术，治疗应用，和即将到来的挑战。此外，还讨论了水溶性差的高血压药物的治疗前景和改善的生物利用度。这篇重点综述了基于MN的高血压药物给药的研究报告和最新进展。为未来的药物用途铺平道路。由于基于MN的药物管理绕过了首过代谢和药物血浆水平的高度变异性，它在全身治疗中变得越来越重要。总之,基于MN的高血压药物递送以提高生物利用度和患者依从性，可以支持高血压药物递送的新趋势，并提供替代选择。克服了当前剂型的限制。
